Key points are not available for this paper at this time.
Our results support the FDA's warning that SGLT2 inhibitors lead to ketoacidosis, as evidenced by an increased reporting rate for acidosis above that in a comparator population treated with DPP4 inhibitors.
Blau et al. (Mon,) studied this question.